日本RNA治療薬市場規模、シェア、競争環境およびトレンド分析レポート：タイプ別（RNA干渉（RNAi）治療薬、mRNA治療薬、アンチセンスオリゴヌクレオチド（ASO）治療薬、その他）、製品別（ワクチン、医薬品）、適応症別（希少遺伝性疾患/遺伝性疾患、感染症、その他）、エンドユーザー別（病院、学術研究センター、受託研究機関、その他）： 2025年から2033年までの機会分析および業界予測

レポートID : ROJP1025891 | 最終更新 : 2025年10月 | フォーマット : : :

JAPAN RNA THERAPEUTICS MARKET REPORT - TABLE OF CONTENTS

1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY

4. VOICE OF CUSTOMER

5. MARKET DYNAMICS

5.1. Market Overview
5.2. Demand Supply Analysis
5.3. Import and Export Analysis
5.4. Value Chain Analysis
5.5. Porter’s Five Forces Analysis
5.6. PESTLE Analysis
5.7. Pricing Analysis
5.8. Market Dynamics
5.9 MARKET DRIVERS
- 5.9.1 Supportive Government Measures Boost Market Expansion
5.10 MARKET RESTRAINTS
- 5.10.1 Challenges in the Delivery and Stability of RNA Molecules are Restraining the Market
5.11 MARKET OPPORTUNITY
- 5.11.1 Rising Issuance of Patents Supports Market Growth
5.12 PORTER'S FIVE FORCE ANALYSIS
- 5.12.1 Bargaining Power of Buyers/Consumers
- 5.12.2 Bargaining Power of Suppliers
- 5.12.3 Threat of New Entrants
- 5.12.4 Threat of Substitute Products
- 5.12.5 Intensity of Competitive Rivalry

6. MARKET SEGMENTATION (Market Size by Value - USD 2025-2033)

6.1 By Type
- 6.1.1. RNA Interference (RNAi) Therapeutics
- 6.1.2. mRNA Therapeutics
- 6.1.3. Antisense Oligonucleotide (ASO)Therapeutics
- 6.1.4. Others
6.2 By Product
- 6.2.1. Vaccines
- 6.2.2. Drugs
6.3 By Indication
- 6.3.1. Rare Genetic Diseases/Hereditary Diseases
- 6.3.2. Infectious Diseases
- 6.3.3 Others
6.4 By End-user
- 6.4.1. Hospitals
- 6.4.2. Academic Research Centers
- 6.4.3 Contract Research Organizations
- 6.4.4. Others
6.5 By Region
- 6.5.1. North [Hokkaido and Tohoku]
- 6.5.2. Central [Kanto and Chubu]
- 6.5.3. South [Kansai, Chugoku, Shikoku, and Kyushu &Okinawa]